The
inhibition
of
residual
tumor
recurrence
while
repairing
bone
defects
poses
a
challenging
issue
for
postoperative
osteosarcoma
treatment.
Here,
we
develop
self-assembling
peptide
hydrogel
(GelA)
the
targeted
delivery
cisplatin
(CDDP),
aiming
to
integrate
with
defect
repair.
GelA
exhibits
exceptional
biocompatibility,
high
loading
capacity
CDDP,
and
superior
adhesion.
After
in
situ
injection
defects,
CDDP-loaded
GelA-CDDP
demonstrates
strong
affinity
hydroxyapatite,
thereby
facilitating
optimal
adhesion
prolonging
retention
time
CDDP
wound.
Furthermore,
can
regulate
distribution
release
behavior
minimizing
off-target
effects
optimizing
therapeutic
outcomes
chemotherapy
osteogenesis.
Finally,
orthotopic
transplantation
model
mice,
treatment
significantly
inhibits
as
well
repair
through
synergistic
osteogenesis
promotion
osteoclastic
inhibition.
We
believe
that
this
hydrogel-based
therapy
strategy
holds
great
promise
achieving
simultaneous
Journal of Translational Medicine,
Journal Year:
2025,
Volume and Issue:
23(1)
Published: April 15, 2025
Endometrial
cancer
ranks
among
the
most
common
gynecological
cancers,
with
increasing
rates
of
incidence
and
death.
Cold
atmospheric
plasma
(CAP)
has
become
a
promising
novel
therapeutic
approach
for
treatment.
Nevertheless,
specific
impact
CAP
on
endometrial
remains
inadequately
characterized.
This
study
aimed
to
investigate
effect
progression
reveal
its
regulatory
mechanisms.
Colony
formation,
EdU,
wound-healing,
transwell
assay
were
used
detect
progression.
Proteomics
is
employed
identify
potential
targets
signaling
pathways
through
which
impacts
cells.
MDA,
lipid
ROS,
JC-1
MMP
assays
ferroptosis.
Immunoprecipitation-mass
spectrometry,
co-immunoprecipitation,
immunofluorescence
co-localization,
molecular
docking
analyze
USP49
HDAC3
interactions.
The
tumor
xenografts
model
determined
that
inhibits
growth
in
vivo.
observed
significant
inhibitory
proliferation
migration
cells
reported
first
time
induces
ferroptosis
Mechanistically,
activated
transcription
p53
by
modulating
mediated
histone
H3K18
lactylation,
resulting
upregulation
driving
cell
interaction
between
was
validated
mass
spectrometry
co-immunoprecipitation
experiments.
regulation
contingent
upon
USP49,
wherein
down-regulation
augments
ubiquitination
HDAC3,
consequently
diminishing
protein
stability.
Furthermore,
animal
models
transplanted
tumors
corroborated
Our
findings
illustrate
suppressive
treatment
uncover
mechanism
CAP.
Specifically,
modulates
pathway
HDAC3/H3K18la/p53
axis,
presenting
Small Methods,
Journal Year:
2023,
Volume and Issue:
8(1)
Published: Oct. 17, 2023
Abstract
Despite
the
tremendous
progress
in
cancer
treatment
recent
decades,
cancers
often
become
resistant
due
to
multiple
mechanisms,
such
as
intrinsic
or
acquired
multidrug
resistance,
which
leads
unsatisfactory
effects
accompanying
metastasis
and
recurrence,
ultimately
failure.
With
a
deeper
understanding
of
molecular
mechanisms
tumors,
researchers
have
realized
that
designs
targeting
tumor
resistance
would
be
promising
strategy
break
therapeutic
deadlock.
Nanodelivery
systems
excellent
physicochemical
properties,
including
highly
efficient
tissue‐specific
delivery,
substantial
specific
surface
area,
controllable
chemistry,
endow
nanodelivery
with
capabilities
precise
targeting,
deep
penetration,
responsive
drug
release,
codelivery,
multimodal
synergy,
are
currently
widely
used
biomedical
researches
bring
new
dawn
for
overcoming
resistance.
Based
on
this
review
summarizes
research
improve
efficacy
years
offers
prospects
challenges
application
APOPTOSIS,
Journal Year:
2024,
Volume and Issue:
unknown
Published: June 9, 2024
Abstract
Ferroptosis
is
a
form
of
cell
death
that
triggered
by
the
presence
ferrous
ions
and
characterized
lipid
peroxidation
induced
these
ions.
The
mechanism
exhibits
distinct
morphological
characteristics
compared
to
apoptosis,
autophagy,
necrosis.
A
notable
aspect
ferroptosis
its
ability
inhibit
uncontrolled
tumor
replication
immortalization,
especially
in
malignant,
drug-resistant,
metastatic
tumors.
Additionally,
immunotherapy,
novel
therapeutic
approach
for
tumors,
has
been
found
have
reciprocal
regulatory
relationship
with
context
anti-tumor
therapy.
comprehensive
analysis
immunotherapy
therapy
presented
this
paper,
highlighting
potential
mutual
adjuvant
effects.
Specifically,
we
discuss
mechanisms
underlying
emphasizing
their
improve
immune
microenvironment
enhance
immunotherapeutic
Furthermore,
investigate
how
factors
may
increase
sensitivity
cells
ferroptosis.
We
aim
provide
prospective
view
promising
value
combined
anticancer
elucidating
network
between
each.
Graphical
involves
intricate
crosstalk
cells.
Through
MHC
recognition,
CD8
+
T
activate
JAK1/STAT1
pathway
cells,
impairing
function
System
Xc
reducing
GSH
GPX4
expression
promote
activation
STAT1-IRF1-ACSL4
could
also
blockade
antioxidant
induces
ferroptosis,
released
DAMPs
DCs
maturation
through
cGAMP-STING-TBK1
pathway,
leading
antigen
presentation
activates
release
M1-type
polarization
macrophages,
which
exerts
an
effect.
effects
be
enhanced
blocking
inhibitory
checkpoints
such
as
PD-1,
PD-L1,
CTLA4,
LAG3.
Abbreviations:
ACSL4,
acyl-CoA
synthetase
long-chain
family
member
4;
BH4,
tetrahydrobiopterin;
cGAMP,
cyclic
GMP-AMP;
cytotoxic
lymphocyte-associated
antigen-4;
DCs,
dendritic
cells;
DHFR,
dihydrofolate
reductase;
DHODH,
dihydroorotate
dehydrogenase;
GPX4,
glutathione
peroxidase
GSH,
glutathione;
HIF-1α,
Hypoxia-Inducible
Factor-1α;IFN-γ,
interferon-γ;
IRF1,
interferon
factor
1;IRP1,
iron
protein
1;
JAK
1,
janus
kinase;
LAG3,
lymphocyte
gene
3;
MHC,
major
histocompatibility
complex;
NRF2,
nuclear
erythroid-2-related
2;
programmed
-1;
ligand
PUFA,
polyunsaturated
fatty
acid;
ROS,
reative
oxygen
species;
STAT1,
signal
transducer
activator
transcription
STING,
stimulator
genes;
TBK1,
TANK-binding
kinase
1
TLR2,
toll-like
receptor
2.
This
diagram
was
drawn
Figdraw
(
www.figdraw.com
).
The
inhibition
of
residual
tumor
recurrence
while
repairing
bone
defects
poses
a
challenging
issue
for
postoperative
osteosarcoma
treatment.
Here,
we
develop
self-assembling
peptide
hydrogel
(GelA)
the
targeted
delivery
cisplatin
(CDDP),
aiming
to
integrate
with
defect
repair.
GelA
exhibits
exceptional
biocompatibility,
high
loading
capacity
CDDP,
and
superior
adhesion.
After
in
situ
injection
defects,
CDDP-loaded
GelA-CDDP
demonstrates
strong
affinity
hydroxyapatite,
thereby
facilitating
optimal
adhesion
prolonging
retention
time
CDDP
wound.
Furthermore,
can
regulate
distribution
release
behavior
minimizing
off-target
effects
optimizing
therapeutic
outcomes
chemotherapy
osteogenesis.
Finally,
orthotopic
transplantation
model
mice,
treatment
significantly
inhibits
as
well
repair
through
synergistic
osteogenesis
promotion
osteoclastic
inhibition.
We
believe
that
this
hydrogel-based
therapy
strategy
holds
great
promise
achieving
simultaneous
